Robert Buynak
Clinical Trial Investigators(US)Velocity Clinical Research (United States)(US)Radiology Associates of Albuquerque(US)
Publications by Year
Research Areas
Hepatitis C virus research, SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Pain Mechanisms and Treatments, Systemic Lupus Erythematosus Research
Most-Cited Works
- → Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study(2010)250 cited
- → Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study(2010)179 cited
- → RNA Interference With Zilebesiran for Mild to Moderate Hypertension(2024)107 cited
- → Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial(2015)43 cited
- → Interferon‐free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND‐C3, a Phase 2b study(2014)21 cited
- → 2006 GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN SIGNIFICANTLY IMPROVES VIROLOGIC RESPONSE AND ALT NORMALIZATION AT END-OF-TREATMENT AND IMPROVES SVR24 COMPARED TO PEG-IFN/RIBAVIRIN IN GENOTYPE-1 CHRONIC HCV PATIENTS